Jack Ragheb to Speak at Immunotoxicity conference Jan 31 - Feb 1, 2013 in San Diego, CA
Jack A. Ragheb, M.D., Ph.D. Principal Investigator at the Laboratory of Immunology in the Division of Therapeutic Proteins Office of Biological Products, CDER, FDA Will Give a Presentation at the Inaugural Immunogenicity and Immunotoxicity Conference on Jan 31 - Feb 1, 2013 in San Diego, CA.
- San Diego, CA (1888PressRelease) December 06, 2012 - Jack Ragheb, Principal Investigator at the Laboratory of Immunology in the Division of Therapeutic Proteins Office of Biological Products, CDER, FDA Will Give a Presentation at the Inaugural Immunogenicity and Immunotoxicity Conference on Jan 31 - Feb 1, 2013 in San Diego, CA
Jack A. Ragheb, M.D. Ph.D. is a Senior Regulatory Research Officer and Principal Investigator in the Division of Therapeutic Proteins/OBP/OPS/CDER/FDA and an Attending Physician on the Allergy Immunology Service, NIAID in the National Institutes of Health, Bethesda, MD. A graduate of the Johns Hopkins University and School of Medicine, he performed his clinical training at the Johns Hopkins Hospital and National Institutes of Health. A recipient of numerous research awards, his work and publications has spanned the fields of retrovirology, gene therapy, immune activation, and clinical trials in immune tolerance. He is actively investigating the use of humanized mouse models to predict the immunogenicity of therapeutic proteins.
In addition to Dr. Ragheb's presentation, Steve Swanson from Amgen and Jacques Descotes from University General Hospitals will also present and the keynote address will be given by Anne De Groot from EpiVax.
The Inaugural Immunogenicity and Immunotoxicity conference will bring together a mix of academic and industry experts from leading affiliations, such as MedImmune, Roche, Ambryx, Aegis Therapeutics, Antitope, Epiontis, Amgen, EpiVax, Ablynx, Eleven Biotherapeutics, and Bayer HealthCare, to cover many current and relevant aspects of Immunogenicity and Immunotoxicity.
This conference is also part of the 2nd Novel Immunotherapeutics Summit, which consists of this track and three other tracks:
1) 5th Immunotherapeutics and Immunomonitoring
2) 11th Cytokines and Inflammation
3) 2nd Allergy Drug Discovery
For more information, please visit www.gtcbio.com
###
space
space
Satisfied Users & 
Approved Press Releases
Print
Email
Report Spam